OrthoPediatrics: 3 Key Takeaways for Long-Term Investors

OrthoPediatrics raised its 2026 revenue guidance to $270-273 million, with Q3 revenue growing 19% year-over-year to $72.7 million. The company is benefiting from a product super cycle with new pediatric surgical implants, expansion of its non-surgical bracing clinic network to over 60 locations, and disciplined capital allocation that has generated positive free cash flow of $1.6 million in Q3.